within Pharmacolibrary.Drugs.ATC.R;

model R07AB07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 3.6 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.245,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0026666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Almitrine is a respiratory stimulant formerly used for the treatment of chronic obstructive pulmonary disease (COPD) and hypoxemic conditions. It acts primarily via peripheral chemoreceptor stimulation, enhancing alveolar ventilation and thus improving oxygenation. Its use has become limited or discontinued in most countries due to concerns over peripheral neuropathy and lack of robust efficacy data.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on adult subjects after oral single-dose administration of almitrine in a clinical study.</p><h4>References</h4><ol><li><p>Stavchansky, S, et al., &amp; Geary, RS (1989). Single oral dose proportionality pharmacokinetics of almitrine bismesylate in humans. <i>Biopharmaceutics &amp; drug disposition</i> 10(3) 229–237. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2510100302&quot;>10.1002/bdd.2510100302</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2566337/&quot;>https://pubmed.ncbi.nlm.nih.gov/2566337</a></p></li><li><p>Bury, T, et al., &amp; Radermecker, M (1989). Dose-response and pharmacokinetic study with almitrine bismesylate after single oral administrations in COPD patients. <i>The European respiratory journal</i> 2(1) 49–55. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2495983/&quot;>https://pubmed.ncbi.nlm.nih.gov/2495983</a></p></li><li><p>Magny, JF, et al., &amp; Dehan, M (1987). Study of the pharmacokinetics and pharmacodynamic activity of almitrine bismesylate in infants during the recovery phase following bronchopulmonary dysplasia. <i>Developmental pharmacology and therapeutics</i> 10(5) 369–376. DOI:<a href=&quot;https://doi.org/10.1159/000457766&quot;>10.1159/000457766</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2888611/&quot;>https://pubmed.ncbi.nlm.nih.gov/2888611</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R07AB07;
